Upgrade to SI Premium - Free Trial

Ocuphire Pharma (OCUP) Announces US Launch of RYZUMVl

April 1, 2024 7:15 AM

Ocuphire Pharma, Inc. (Nasdaq: OCUP) today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS).

Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine Ophthalmic Solution 0.75%. Under the terms of this agreement, Ocuphire is eligible to receive regulatory and commercial milestones as well as royalties.

For more information, please refer to the announcement on the Viatris corporate website at https://newsroom.viatris.com/.

Categories

Corporate News FDA

Next Articles